Version 1
: Received: 11 February 2023 / Approved: 14 February 2023 / Online: 14 February 2023 (08:39:01 CET)
How to cite:
Mendiratta, M.; Mendiratta, M.; Mohanty, S.; Sahoo, R.K.; Prakash, H. Employing Mesenchymal Stromal Cells (MSC) for Managing Acute and Chronic Graft-versus-Host-Disease. Preprints2023, 2023020240. https://doi.org/10.20944/preprints202302.0240.v1
Mendiratta, M.; Mendiratta, M.; Mohanty, S.; Sahoo, R.K.; Prakash, H. Employing Mesenchymal Stromal Cells (MSC) for Managing Acute and Chronic Graft-versus-Host-Disease. Preprints 2023, 2023020240. https://doi.org/10.20944/preprints202302.0240.v1
Mendiratta, M.; Mendiratta, M.; Mohanty, S.; Sahoo, R.K.; Prakash, H. Employing Mesenchymal Stromal Cells (MSC) for Managing Acute and Chronic Graft-versus-Host-Disease. Preprints2023, 2023020240. https://doi.org/10.20944/preprints202302.0240.v1
APA Style
Mendiratta, M., Mendiratta, M., Mohanty, S., Sahoo, R.K., & Prakash, H. (2023). Employing Mesenchymal Stromal Cells (MSC) for Managing Acute and Chronic Graft-versus-Host-Disease. Preprints. https://doi.org/10.20944/preprints202302.0240.v1
Chicago/Turabian Style
Mendiratta, M., Ranjit Kumar Sahoo and Hridayesh Prakash. 2023 "Employing Mesenchymal Stromal Cells (MSC) for Managing Acute and Chronic Graft-versus-Host-Disease" Preprints. https://doi.org/10.20944/preprints202302.0240.v1
Abstract
Mesenchymal Stromal Cells (MSCs) are multipotent, non-hematopoietic progenitor cells with a wide range of immune conditioning and regenerative potential which qualify them as potential component of cell based therapy for various autoimmune / chronic inflammatory ailments. Their immunomodulatory properties include the secretion of immunosuppressive cytokines, the ability to suppress T-cell activation and differentiation, and the induction of regulatory T-cells. In view of this and our interest, we here discuss the significance of MSC for the management of Graft-versus-Host Disease (aGVHD), one of the autoimmune manifestation in human.. In pre-clinical models, MSCs have been shown to reduce the severity of aGVHD symptoms, including skin and gut damage, which are the most common and debilitating manifestations of this disease. While initial clinical studies of MSCs in aGVHD cases were promising, the results were variable in randomized studies. So, further studies are warranted to fully understand their potential benefits, safety profile, and optimal dosing regimens. In view of these inevitable issues, here we discuss various mechanisms, how MSCs can be employed in managing aGVHD, as a therapeutic option for this disease.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
*
